Tirzepatide for weight loss
Avg Loss
22.5%
Trial
72wk
Frequency
Weekly
FDA
Approved
Overview
Tirzepatide is the FDA-approved dual-agonist (GLP-1 + GIP) that demonstrated 22.5% average weight loss in the SURMOUNT-1 trial over 72 weeks. The GIP component reduces nausea relative to pure GLP-1 drugs, which is the main reason it tends to be better tolerated than equivalent-dose semaglutide. In the Philippines, branded Mounjaro is at international hospitals; research-grade tirzepatide is widely available from peptide suppliers.
Why tirzepatide is the most popular choice
A-01
Extensive safety data
FDA-approved with large Phase 3 SURMOUNT trials involving thousands of participants. Most well-studied weight loss peptide available.
A-02
Excellent tolerability
GIP component reduces nausea significantly compared to GLP-1-only drugs. Better tolerated than equivalent-dose semaglutide for most users.
A-03
Proven results
22.5% average weight loss in SURMOUNT-1. 87% of participants achieved at least 5% weight loss. Real-world results match trials.
Standard titration protocol
| Phase | Dose | Duration | Expected effect |
|---|---|---|---|
| Starting | 2.5mg | Weeks 1–4 | Tolerance building, mild appetite changes |
| Titration 1 | 5mg | Weeks 5–8 | Clear appetite suppression, first weight loss |
| Titration 2 | 7.5mg | Weeks 9–12 | Accelerated fat loss |
| Titration 3 | 10mg | Weeks 13–16 | Near maximum therapeutic effect |
| Target | 10–15mg | Ongoing | Maintenance and continued loss |
Generic research tirzepatide may be dosed differently than pharmaceutical Mounjaro pens. Verify mg per unit with your supplier.
Expected results timeline
2.5mg
Subtle appetite changes. Some users notice less interest in food. Minimal weight loss — primarily a tolerance-building phase.
5–7.5mg
Clear, noticeable appetite suppression. Food intake drops naturally. Weight loss becomes consistent — typically 0.5–1.5kg per week.
10–15mg
Maximum weight loss phase. Many users describe near-complete suppression of hunger. Rapid body composition changes. 10–20% total loss achievable.
Long-term
Weight loss slows as body weight decreases (fewer calories to cut). Maintenance becomes the goal. Many users stay at 10mg long-term.
Not losing weight?
- 01If you are not losing weight on 2.5mg, this is expected — it is a titration dose. Increase to 5mg after 4 weeks.
- 02At 5mg+, if weight stalls: track actual caloric intake. Tirzepatide suppresses hunger but does not prevent eating above maintenance.
- 03Check that you are using subcutaneous injection correctly (not intramuscular, not intravenous).
- 04Ensure peptide is being stored correctly (refrigerated, not frozen after reconstitution).
- 05Verify COA and product authenticity — underdosed or counterfeit product is a common cause.
- 06Medical causes: thyroid issues, medications that cause weight gain, or metabolic adaptation — consult a doctor.
Rebound warning
↗ Related Filings